11 Myths About Menopause and Sexual Desire That Harm Women and Their Partners
The thing that stings most about this topic is how many women quietly conclude they are broken — or that their relationship is broken — when what is actually happening is a measurable hormonal shift that has names, mechanisms, and options. Nobody told them that, and that gap in information is not a small thing.
Learn more about Rose →Myth: Losing sexual desire at menopause is universal and inevitable
Population studies consistently show that roughly 40–55% of women report a meaningful decline in sexual desire during perimenopause or menopause — which means a substantial proportion do not. Desire is shaped by testosterone, estrogen, relationship quality, sleep, mental health, and cultural context, meaning there is no single biological destiny here. Treating low desire as a foregone conclusion prevents women from investigating the specific drivers that are actually changeable.
Myth: Estrogen is the only hormone that matters for female desire
Testosterone is now well-established as the primary hormonal driver of sexual desire in women, just as it is in men, even though women produce it at much lower absolute levels. Testosterone acts on androgen receptors throughout the brain — including the hypothalamus — and in genital tissue, supporting both mental interest and physical arousal. Estrogen matters enormously for comfort and tissue health, but targeting it alone while ignoring testosterone leaves the neurological side of desire largely unaddressed.
Myth: If sex is painful, desire will naturally disappear and that's just ageing
Genitourinary syndrome of menopause (GSM) — which causes vaginal dryness, tissue thinning, and pain during sex — is a direct, physiological consequence of falling estrogen, not a vague side-effect of getting older. When sex hurts, the brain rapidly learns to suppress arousal and interest through a conditioned avoidance response that is entirely logical and entirely reversible. Treating the underlying tissue changes with local estrogen, ospemifene, or other evidence-based options frequently restores the physical conditions under which desire can re-emerge.
Myth: Low libido at menopause is a psychological problem, not a physical one
This framing has historically been used to dismiss women's symptoms and delay effective treatment, but the physiology is unambiguous: testosterone decline reduces dopaminergic signalling in reward pathways, estrogen loss alters serotonin and opioid receptor sensitivity, and GSM creates pain that directly inhibits arousal. None of these are personality flaws or signs of emotional dysfunction. Psychological factors — stress, relationship conflict, body image — absolutely interact with biology, but they do not cause the underlying hormonal shift.
Myth: Hormone therapy makes no difference to sexual desire
Multiple randomised controlled trials show that testosterone therapy in postmenopausal women significantly increases satisfying sexual events, desire, and arousal compared to placebo — effects that are independent of mood improvement. Systemic estrogen therapy also improves desire indirectly by resolving sleep disruption, reducing hot flushes, and improving vaginal comfort, all of which lower the physiological burden that suppresses libido. The evidence base here is strong enough that major menopause societies now formally endorse testosterone for hypoactive sexual desire disorder in postmenopausal women.
Myth: A woman's partner is the problem if she's lost interest in sex
Partners often internalise a woman's decline in desire as personal rejection, which is an understandable but physiologically uninformed conclusion. When testosterone drops, the brain's motivational drive toward sexual initiation diminishes at a neurochemical level that has nothing to do with attraction to a specific person. Recognising that the change is hormonal — not relational — is not only more accurate, it also opens a completely different and far more productive conversation between partners.
Myth: Women who had high libido before menopause will be fine
Prior sexual history does not reliably predict how menopause will affect desire, because the hormonal changes at menopause are superimposed on whatever baseline a woman had — they don't cancel out. A woman with a previously strong drive can experience a significant decline simply because testosterone and estrogen fall below the threshold her particular neurobiology needs to sustain that drive. Conversely, some women with previously low desire notice little change, because their baseline was already below the threshold for hormonal sensitivity.
Myth: Antidepressants prescribed for menopause mood symptoms won't affect desire
SSRIs and SNRIs are commonly prescribed for perimenopausal depression and anxiety, and sexual side effects — including reduced desire, delayed orgasm, and reduced genital sensation — are among the most common reasons women discontinue them. This is not a rare edge case: studies suggest up to 70% of people on SSRIs experience some sexual dysfunction. Women deserve to know this trade-off explicitly before starting treatment, and to know that alternatives exist, including hormone therapy, which addresses both mood and desire through a different mechanism.
Myth: If a woman isn't thinking about sex spontaneously, her desire is broken
Sex researcher Rosemary Basson's influential responsive desire model, now widely adopted in sexual medicine, describes a pattern — common in women and more common still as they age — where desire emerges in response to erotic stimuli rather than arising spontaneously out of nowhere. This is not dysfunction; it is a recognised and normal desire architecture that simply requires a different approach to initiation. Many women (and their partners) find that desire appears once they are engaged, even if it was entirely absent beforehand.
Myth: Vaginal lubricants and moisturisers are sufficient treatment for desire loss
Lubricants and vaginal moisturisers are genuinely useful for reducing friction and discomfort during sex, but they address the mechanical surface of the problem and have no effect whatsoever on the neurological and hormonal drivers of desire itself. Relying solely on these products while the underlying estrogen and testosterone deficiency continues unaddressed is a bit like putting better tyres on a car with an empty fuel tank. They belong in the toolkit, but not as a substitute for evaluating what is actually driving the loss of interest.
Myth: It's too late to address this if menopause happened years ago
There is no established biological cut-off after which addressing hormonal drivers of sexual desire becomes ineffective, and postmenopausal women in their 60s and 70s are included in testosterone therapy trials with meaningful results. Local estrogen can reverse GSM tissue changes at any point after menopause, because the tissue retains the capacity to respond to estrogen regardless of how long the deficiency lasted. The idea that a woman has 'missed the window' is not supported by evidence and functions mainly as a reason to stop asking.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.